An Extension Study to Evaluate the Long-Term Safety of QGE031 in Chronic Spontaneous Urticaria Patients from a Previous Study

Overview

About this study

The purpose of this extension study is to evaluate the long-term safety of QGE031 when given to patients with chronic spontaneous urticaria who completed the previous study CQGE031C2201.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • To be eligible for inclusion in this study all of the following criteria must be fulfiled
    • Written informed consent must be obtained before any assessment is performed
    • Patients who complete the treatment epoch in study CQGE031C2201 and complete at least visit 203 (Week 32 of the follow-up epoch, ≥16 weeks after last injection) and present with active disease as defined by UAS7 ≥12
    • Patients must not have any missing eDiary entries in the 7 days prior to visit 301 (patients are allowed to repeat until this criterion is met)
    • Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules

Exclusion Criteria:

  • Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria 
  • Evidence of parasitic infection 
  • Any other skin diseases than chronic spontaneous urticaria with chronic itching 
  • Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine 
  • History of anaphylaxis 
  • History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study
  • History of hypersensitivity to any of the study drugs or its components of similar chemical classes 
  • Pregnant or nursing (lactating) women
  • Other protocol-defined inclusion/exclusion criteria may apply

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Gerald Volcheck, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20256938

Mayo Clinic Footer